Inspire Medical Systems Analysts Lower Their Forecasts After Q2 Results

Inspire Medical Systems (INSP) reported second-quarter earnings and sales that surpassed analyst consensus estimates, with EPS of $0.45 against $0.21 and sales of $217.086 million against $214.480 million. However, the company drastically cut its FY2025 GAAP EPS guidance from $2.20-$2.30 to $0.40-$0.50 and sales guidance from $940.000 million-$955.000 million to $900.000 million-$910.000 million. This significant reduction in future outlook caused INSP shares to plummet 40.6% and led to multiple analyst downgrades and substantial price target reductions across the board.

Analysis

Inspire Medical Systems (INSP) experienced a severe market repricing, with its shares plummeting 40.6% after the company drastically reduced its full-year 2025 guidance. The company slashed its FY25 GAAP EPS forecast from a range of $2.20-$2.30 to just $0.40-$0.50 and trimmed its sales outlook from $940-$955 million to $900-$910 million. This bleak forward outlook completely overshadowed an otherwise strong second-quarter performance, where INSP beat consensus estimates with an EPS of $0.45 and sales of $217.086 million. Management's positive commentary regarding the full launch of its new Inspire V system was insufficient to counter the negative financial revisions. The severity of the guidance cut triggered a wave of analyst actions, including downgrades to Neutral/Hold and substantial price target reductions across the board, signaling a broad-based, negative reassessment of the company's near-term growth and profitability trajectory.

Key Decisions for Investors

• Investors should recognize that the significant FY25 guidance cut has completely overshadowed the second-quarter earnings beat, and the market is now pricing the stock based on a sharply lower growth and profitability outlook.
• Given the 40.6% stock decline and the broad-based, aggressive cuts to analyst price targets, it is prudent to await clarity on the drivers behind the guidance reduction and tangible evidence of the Inspire V system's commercial traction before considering a new position.
• Existing shareholders must re-evaluate their investment thesis, as the path to prior valuation levels is now significantly challenged and dependent on the company's ability to restore confidence and deliver on its revised, lower targets.
• Monitor for the upcoming clinical evidence on the Inspire V system, which management has flagged, as this will be a critical data point in assessing whether the new technology can help stabilize the company's financial trajectory.